Literature DB >> 26464705

Blood-based DNA methylation of DNA repair genes in the non-homologous end-joining (NEHJ) pathway in patient with glioma.

Chengcheng Zhou1, Hailiang Tang1, Jian Yu1, Dongxiao Zhuang1, Haishi Zhang1.   

Abstract

UNLABELLED: To investigate the blood-based DNA methylation of repair genes including LIG4, XRCC4, XRCC5, XRCC6 and XRCC7 that involved in non-homologous end-joining (NEHJ) DNA repair pathway in patients with glioma. Blood samples were obtained from 114 glioma patients, 96 normal controls, and 81 glioma patients after radiotherapy and chemotherapy. Blood-based DNA methylation of the five NHEJ repair genes was assayed by methylation-specific polymerase chain reaction (MSP). The DNA methylation level of XRCC5 and XRCC7 in glioma group are significantly higher than those of normal group (P<0.001). Moreover, radiotherapy treatment significantly increased methylation level of XRCC5 and XRCC7 compared to glioma group. No significant difference for the methylation of the other three genes, LIG4, XRCC4 and XRCC6 were detected among three groups. IN
CONCLUSION: our findings indicate that DNA methylation modification plays an important role to regulate the gene expression of XRCC5 and XRCC7, from the results that the gene methylation level of the glioma group is higher than that of the normal group. Increased methylation of XRCC5 and XRCC7 in blood samples of glioma patients and patients with radiotherapy and chemotherapy suggests that blood-based methylation level of XRCC5 and XRCC7 could be a potential indicator for evaluating of the effect of radiotherapy and chemotherapy for glioma patient.

Entities:  

Keywords:  DNA repair gene; Methylation; glioma; non-homologous end-joining

Mesh:

Substances:

Year:  2015        PMID: 26464705      PMCID: PMC4583937     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  13 in total

Review 1.  The DNA double-strand break response in the nervous system.

Authors:  Clint W Abner; Peter J McKinnon
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

Review 2.  The mechanism of human nonhomologous DNA end joining.

Authors:  Michael R Lieber
Journal:  J Biol Chem       Date:  2007-11-12       Impact factor: 5.157

Review 3.  The endless tale of non-homologous end-joining.

Authors:  Eric Weterings; David J Chen
Journal:  Cell Res       Date:  2008-01       Impact factor: 25.617

4.  Processing of DNA for nonhomologous end-joining is controlled by kinase activity and XRCC4/ligase IV.

Authors:  Joe Budman; Sunny A Kim; Gilbert Chu
Journal:  J Biol Chem       Date:  2007-01-31       Impact factor: 5.157

5.  DNA ligase IV is a potential molecular target in ACNU sensitivity.

Authors:  Natsuko Kondo; Akihisa Takahashi; Eiichiro Mori; Taichi Noda; Xiaoming Su; Ken Ohnishi; Peter J McKinnon; Toshisuke Sakaki; Hiroyuki Nakase; Koji Ono; Takeo Ohnishi
Journal:  Cancer Sci       Date:  2010-04-10       Impact factor: 6.716

6.  Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma.

Authors:  Yanhong Liu; Haishi Zhang; Keke Zhou; Lina Chen; Zhonghui Xu; Yu Zhong; Hongliang Liu; Rui Li; Yin Yao Shugart; Qingyi Wei; Li Jin; Fengping Huang; Daru Lu; Liangfu Zhou
Journal:  Carcinogenesis       Date:  2007-03-26       Impact factor: 4.944

7.  Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma.

Authors:  Yanhong Liu; Keke Zhou; Haishi Zhang; Yin Yao Shugart; Lina Chen; Zhonghui Xu; Yu Zhong; Hongliang Liu; Li Jin; Qingyi Wei; Fengping Huang; Daru Lu; Liangfu Zhou
Journal:  Hum Mutat       Date:  2008-03       Impact factor: 4.878

8.  Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells.

Authors:  Takashi Nishikawa; Anupama Munshi; Michael D Story; Sheikh Ismail; Craig Stevens; Sunil Chada; Raymond E Meyn
Journal:  Oncogene       Date:  2004-09-16       Impact factor: 9.867

9.  DNA ligase IV as a new molecular target for temozolomide.

Authors:  Natsuko Kondo; Akihisa Takahashi; Eiichiro Mori; Ken Ohnishi; Peter J McKinnon; Toshisuke Sakaki; Hiroyuki Nakase; Takeo Ohnishi
Journal:  Biochem Biophys Res Commun       Date:  2009-07-15       Impact factor: 3.575

Review 10.  An oncogene-induced DNA damage model for cancer development.

Authors:  Thanos D Halazonetis; Vassilis G Gorgoulis; Jiri Bartek
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

View more
  5 in total

Review 1.  Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update.

Authors:  Pere Llinàs-Arias; Manel Esteller
Journal:  Open Biol       Date:  2017-09       Impact factor: 6.411

Review 2.  Epigenetic heterogeneity in cancer.

Authors:  Mingzhou Guo; Yaojun Peng; Aiai Gao; Chen Du; James G Herman
Journal:  Biomark Res       Date:  2019-10-31

3.  Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma.

Authors:  I-Neng Lee; Jen-Tsung Yang; Cheng Huang; Hsiu-Chen Huang; Yu-Ping Wu; Jui-Chieh Chen
Journal:  Oncol Lett       Date:  2021-04-06       Impact factor: 2.967

Review 4.  Genomic Instability and Cancer Risk Associated with Erroneous DNA Repair.

Authors:  Ken-Ichi Yoshioka; Rika Kusumoto-Matsuo; Yusuke Matsuno; Masamichi Ishiai
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

5.  High Expression of XRCC6 Promotes Human Osteosarcoma Cell Proliferation through the β-Catenin/Wnt Signaling Pathway and Is Associated with Poor Prognosis.

Authors:  Bin Zhu; Dongdong Cheng; Shijie Li; Shumin Zhou; Qingcheng Yang
Journal:  Int J Mol Sci       Date:  2016-07-22       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.